- Home
- XAIR vs SNSE Comparison
XAIR vs SNSE Comparison
Compare XAIR & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | SNSE |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 12.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | XAIR | SNSE |
|---|---|---|
| Price | $0.88 | $11.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $11.00 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 144.0K | 71.4K |
| Earning Date | 02-09-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,802,000.00 | N/A |
| Revenue This Year | $128.45 | N/A |
| Revenue Next Year | $153.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $0.67 | $5.00 |
| 52 Week High | $10.40 | $18.35 |
Technical Indicators
Market Signals| Indicator | XAIR | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 63.88 |
| Support Level | $0.78 | $8.37 |
| Resistance Level | $0.98 | $11.35 |
| Average True Range (ATR) | 0.07 | 1.03 |
| MACD | 0.04 | 0.27 |
| Stochastic Oscillator | 69.06 | 94.56 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).